Malarone

Atovaquone/proguanil, the active ingredient in Malarone, is an antimalarial presented as a tablet for oral use. It is used to prevent malaria in travelers and to treat acute uncomplicated Plasmodium falciparum infections in patients at risk. The combination works synergistically to inhibit parasite replication and is recommended for both prophylaxis and therapy in endemic regions.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone is an antimalarial medication indicated for both prevention and treatment of malaria caused by Plasmodium species.

- Malaria prophylaxis: prevents infection in travelers to endemic regions when taken before, during, and after exposure. - Treatment of acute uncomplicated malaria: clears Plasmodium falciparum infection in patients with confirmed disease. - Chemoprophylaxis for chloroquine‑resistant malaria: provides protection where chloroquine resistance is prevalent.

Malarone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Abdominal pain - Headache - Vomiting - Diarrhoea - Loss of appetite

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic injury or elevated liver enzymes - Hemolysis in patients with G6PD deficiency - Anaphylaxis or severe allergic reactions - Blood dyscrasias including neutropenia

Before using Malarone, consider the following safety measures.

- Pregnancy: consult a healthcare provider as safety data are limited. - Breastfeeding: weigh potential benefits against possible risks to the infant. - Renal impairment: dose adjustment may be required in severe kidney disease. - Known drug resistance: avoid use in areas with documented resistance to atovaquone‑proguanil. - Concomitant medications: review all current drugs for possible interactions. - Store at ambient temperature: keep in the original pack, protect from moisture.

Malarone can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Rifampin: markedly reduces atovaquone plasma levels, compromising effectiveness. - Protease inhibitors (e.g., ritonavir): may increase atovaquone concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Antacids containing aluminium or magnesium: can decrease absorption of atovaquone. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - CYP3A4 inducers such as carbamazepine: may lower atovaquone exposure. - Certain antiretrovirals (e.g., efavirenz): may modestly reduce drug levels.